Larimar Therapeutics (LRMR) 10-Q2016 Q2 Quarterly report

Filed: 5 Aug 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: abnormal, acid, Alicia, attrition, binding, black, campaign, cellular, compound, departure, differentiated, dissociate, easily, eleven, embryofetal, enzyme, exhibiting, expertise, factor, fatty, feedback, glucose, glycemic, great, inhibition, insomnia, leadership, liver, Loustau, margin, minimize, morale, optimized, Patrick, pioneered, potency, potent, president, reallocation, refocusing, release, resignation, restructuring, retention, Secor, senior, shelf, stored, suggest, teratogenicity, testicular, tone, toxicity, turnover, unintended, ununderstood, vastly, vice, withdrew, workforce

Removed: account, addressable, adolescent, adult, AEs, age, agonist, aid, Alize, analog, analogue, behavior, boxed, brain, broader, carbetocin, carcinogenicity, category, Chong, CKD, clinically, closed, CMO, commenced, contraindicated, controlled, correctly, Covidien, craniopharyngioma, CRO, Dang, declared, defective, demonstrated, designated, designation, device, diazoxide, discount, dispensing, eat, English, establishing, expansion, explore, Ferring, forecast, forecasted, frequently, functioning, geography, ghrelin, hormone, hypothesized, impaired, inclusive, initially, initiation, injectable, kit, Korea, Kun, maintained, measuring, medicinal, melanocortin, moiety, month, narrower, neurophysiological, orphan, overallotment, oxytocin, pediatric, peptide, Pharma, pharmacological, physical, polymorph, Prader, precision, pregnancy, Published, raw, receptor, registry, regular, regulating, replicate, requirement, Resupply, Rhythm, rolling, safer, show, South, stability, statistically, sterile, subjective, subsequently, suffering, sufficiently, surgery, syringe, targeting, Termination, thereunder, train, translate, trust, unacylated, unrecognized, urgently, validate, validated, validating, Willi, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

LRMR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Zafgen, Inc. (the “Company”) for the period ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his or her knowledge:

1)	the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 5, 2016				/s/ Thomas E. Hughes
				Thomas E. Hughes
				Chief Executive Officer and President
				(Principal Executive Officer)

Dated: August 5, 2016				/s/ Patricia Allen
				Patricia Allen
				Chief Financial Officer
				(Principal Financial and Accounting Officer)